neogenomics laboratories is a leading cancer diagnostic reference laboratory that has provided high-quality cancer testing and partnership programs to pathologists and oncologists for over 10 years. we work every day to achieve our common purpose of saving lives by improving patient care through communication, accuracy, reliability, and efficiency. our areas of expertise include cancer cytogenetics with industry-leading turnaround times; hematologic and solid tumor fish testing with the largest menu of technical-only services available; 10-color flow cytometry; ihc supported by an extensive antibody library; and over 100 molecular oncology tests comprising the most comprehensive combination of multiparameter profiles and targeted biomarker tests in the industry. our technical-only testing programs feature on-demand or live training and are available to pathologists who wish to sign out fish, flow cytometry, and/or ihc. neogenomics’ extremely fast test development cycle means we are hig
Company profile
Ticker
NEO
Exchange
Website
CEO
Douglas M. Van Oort
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AMERICAN COMMUNICATIONS ENTERPRISES INC
SEC CIK
Corporate docs
Subsidiaries
Clarient Diagnostic Services, Inc. • Clarient, Inc. • Cynogen, Inc. • Genesis Acquisition Holdings Corp. • Genoptix, Inc. • Inivata Limited • Inivata, Inc. • Minuet Diagnostics, Inc. • NeoGenomics Bioinformatics, Inc. • NeoGenomics Europe, SA ...
IRS number
742897368
NEO stock data
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
24 May 24
10-Q
2024 Q1
Quarterly report
30 Apr 24
8-K
NeoGenomics Reports First Quarter 2024 Results
30 Apr 24
8-K
Departure of Directors or Certain Officers
18 Apr 24
ARS
2023 FY
Annual report to shareholders
8 Apr 24
DEFA14A
Additional proxy soliciting materials
8 Apr 24
DEF 14A
Definitive proxy
8 Apr 24
8-K/A
Departure of Directors or Certain Officers
26 Feb 24
8-K
Departure of Directors or Certain Officers
23 Feb 24
10-K
2023 FY
Annual report
20 Feb 24
Transcripts
NEO
Earnings call transcript
2024 Q1
30 Apr 24
NEO
Earnings call transcript
2023 Q4
20 Feb 24
NEO
Earnings call transcript
2023 Q3
6 Nov 23
NEO
Earnings call transcript
2023 Q2
8 Aug 23
NEO
Earnings call transcript
2023 Q1
8 May 23
NEO
Earnings call transcript
2022 Q4
23 Feb 23
NEO
Earnings call transcript
2022 Q3
8 Nov 22
NEO
Earnings call transcript
2022 Q2
9 Aug 22
NEO
Earnings call transcript
2022 Q1
27 Apr 22
NEO
Earnings call transcript
2021 Q4
23 Feb 22
Latest ownership filings
4
Anthony P. Zook
4 Jun 24
4
LYNN A. TETRAULT
4 Jun 24
4
David Brian Perez
4 Jun 24
4
Michael Aaron Kelly
4 Jun 24
4
STEPHEN M KANOVSKY
4 Jun 24
4
ALISON L. HANNAH
4 Jun 24
4
Neil Gunn
4 Jun 24
4
Elizabeth Floegel
4 Jun 24
144
Notice of proposed sale of securities
28 May 24
4
Alicia C Olivo
17 May 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 331.91 mm | 331.91 mm | 331.91 mm | 331.91 mm | 331.91 mm | 331.91 mm |
Cash burn (monthly) | 3.52 mm | (no burn) | 10.19 mm | 8.60 mm | 8.64 mm | 1.26 mm |
Cash used (since last report) | 8.07 mm | n/a | 23.32 mm | 19.69 mm | 19.77 mm | 2.89 mm |
Cash remaining | 323.85 mm | n/a | 308.60 mm | 312.23 mm | 312.14 mm | 329.02 mm |
Runway (months of cash) | 91.9 | n/a | 30.3 | 36.3 | 36.1 | 260.2 |
Institutional ownership, Q1 2024
97.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 249 |
Opened positions | 214 |
Closed positions | 1 |
Increased positions | 4 |
Reduced positions | 13 |
13F shares | Current |
---|---|
Total value | 1.80 tn |
Total shares | 125.03 mm |
Total puts | 232.40 k |
Total calls | 1.13 mm |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 19.85 mm | $312.06 bn |
Vanguard | 14.21 mm | $223.40 bn |
Brown Advisory | 9.67 mm | $152.01 bn |
T. Rowe Price Investment Management | 6.86 mm | $107.80 mm |
JHG Janus Henderson | 6.28 mm | $98.73 bn |
STT State Street | 4.90 mm | $76.99 bn |
Greenhouse Funds LLLP | 4.40 mm | $69.11 bn |
MCQEF Macquarie | 4.02 mm | $63.25 bn |
First Light Asset Management | 3.30 mm | $51.91 bn |
Dimensional Fund Advisors | 3.11 mm | $48.84 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Jun 24 | Neil Gunn | RSU Common Stock | Grant | Acquire A | No | No | 0 | 12,254 | 0.00 | 12,254 |
1 Jun 24 | Neil Gunn | Stock Option Common Stock | Grant | Acquire A | No | No | 13.71 | 8,672 | 118.89 k | 8,672 |
1 Jun 24 | Hannah Alison L. | RSU Common Stock | Grant | Acquire A | No | No | 0 | 12,254 | 0.00 | 12,254 |
1 Jun 24 | Hannah Alison L. | Stock Option Common Stock | Grant | Acquire A | No | No | 13.71 | 8,672 | 118.89 k | 8,672 |
1 Jun 24 | Kelly Michael Aaron | RSU Common Stock | Grant | Acquire A | No | No | 0 | 12,254 | 0.00 | 12,254 |
1 Jun 24 | Kelly Michael Aaron | Stock Option Common Stock | Grant | Acquire A | No | No | 13.71 | 8,672 | 118.89 k | 8,672 |
1 Jun 24 | Kanovsky Stephen M | RSU Common Stock | Grant | Acquire A | No | No | 0 | 12,254 | 0.00 | 12,254 |
1 Jun 24 | Kanovsky Stephen M | Stock Option Common Stock | Grant | Acquire A | No | No | 13.71 | 8,672 | 118.89 k | 8,672 |
1 Jun 24 | Zook Anthony P. | RSU Common Stock | Grant | Acquire A | No | No | 0 | 12,254 | 0.00 | 12,254 |
1 Jun 24 | Zook Anthony P. | Stock Option Common Stock | Grant | Acquire A | No | No | 13.71 | 8,672 | 118.89 k | 8,672 |
News
NeoGenomics Introduces Comprehensive Lung Solution & Feature Hematopathology Services At ASCO
28 May 24
NeoGenomics Earnings Analysis: Q1 Recap
10 May 24
BTIG Maintains Buy on NeoGenomics, Lowers Price Target to $21
2 May 24
TD Cowen Maintains Buy on NeoGenomics, Lowers Price Target to $20
1 May 24
Craig-Hallum Assumes NeoGenomics at Buy, Announces Price Target of $26
1 May 24
Press releases
NeoGenomics to Introduce Comprehensive Lung Solution & Feature Hematopathology Services at ASCO, Offering Actionable Insights to Support Treatment Management
28 May 24
NeoGenomics Announces Senior Leadership Promotions
18 Apr 24
NeoGenomics to Report First Quarter 2024 Financial Results on April 30, 2024
9 Apr 24
NeoGenomics Showcases Commitment to Transforming Cancer Patient Care at AACR 2024 Annual Meeting
27 Mar 24